Menu
← Oncology Approval Tracker
FDA DECISION ·
Vegzelma
bevacizumab-adcd · Celltrion
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Bevacizumab biosimilar for labeled uses in colorectal cancer, nonsquamous NSCLC, glioblastoma, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube or primary peritoneal cancer.
LAMPGEN ANALYSIS
Why it matters
The product adds a bevacizumab option for regimens across six cancer categories.
What research teams should watch
Check the disease-specific labeled partner drugs and capture the biosimilar suffix in treatment and safety records.
PRIMARY RECORDS